LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis

被引:94
作者
Wei, Shuquan [1 ]
Wang, Kangwei [2 ]
Huang, Xiaomei [1 ]
Zhao, Zhuxiang [1 ]
Zhao, Ziwen [1 ]
机构
[1] South China Univ Technol, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Guangzhou Peoples Hosp 1, 1 Panfu Rd, Guangzhou 510180, Guangdong, Peoples R China
[2] South China Univ Technol, Affiliated Hosp 2, Dept Pathol, Guangzhou Peoples Hosp 1, Guangzhou, Guangdong, Peoples R China
关键词
lncRNA MALAT1; miR-200a-3p; NSCLC; PD-L1; LONG NONCODING RNA; PROLIFERATION; PD-L1; IMMUNOTHERAPY; EXPRESSION; PATHWAY;
D O I
10.1177/2058738419859699
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study was to investigate the expression correlation between long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (lncRNA MALAT1), miR-200a-3p and programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), and their roles in NSCLC. Real-time polymerase chain reaction (PCR) was performed to detect the expressions of MALAT1, miR-200a-3p and PD-L1 in NSCLC tissues and cells for the correlation analysis. The starBase and Targetscan databases were used to predict the binding sites between MALAT1 and miR-200a-3p, and miR-200a-3p and PD-L1, respectively. The targeting relationship between MALAT1 and miR-200a-3p, and miR-200a-3p and PD-L1 were further verified by real-time PCR and dual luciferase reporter gene assay. Cell proliferation was monitored by CCK8 and colony formation assays. The apoptosis was detected using flow cytometry. Wound healing assay and transwell assay were conducted to determine cell migration and invasion. In this study, we demonstrated that in NSCLC tissues, the expression level of MALAT1 was negatively correlated with that of miR-200a-3p, while positively correlated with PD-L1. Besides, MALAT1 promoted proliferation, mobility, migration, and invasion of NSCLC cells via sponging miR-200a-3p. PD-L1 was validated as a target of miR-200a-3p, and indirectly modulated by MALAT1. In conclusion, LncRNA MALAT1 facilitates the progression of NSCLC by modulating miR-200a-3p/PDL1 axis.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
    Ahn, Beung-Chul
    Pyo, Kyoung-Ho
    Xin, Chun-Feng
    Jung, Dongmin
    Shim, Hyo Sup
    Lee, Chang Young
    Park, Seong Yong
    Yoon, Hong In
    Hong, Min Hee
    Cho, Byoung Chul
    Kim, Hye Ryun
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (06) : 1613 - 1623
  • [2] [Anonymous], FASEB J OFFICIAL PUB
  • [3] [Anonymous], NANOMEDICINE
  • [4] MALAT1 long non-coding RNA and breast cancer
    Arun, Gayatri
    Spector, David L.
    [J]. RNA BIOLOGY, 2019, 16 (06) : 860 - 863
  • [5] What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
    Bravaccini, Sara
    [J]. LUNG CANCER, 2019, 132 : 152 - 153
  • [6] Bray F, 2018, CA: A Cancer Journal for Clinicians, V68, P394
  • [7] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors
    Bylicki, Olivier
    Barazzutti, Helene
    Paleiron, Nicolas
    Margery, Jacques
    Assie, Jean-Baptiste
    Chouaid, Christos
    [J]. BIODRUGS, 2019, 33 (02) : 159 - 171
  • [8] Chang H, 2018, AM J TRANSL RES, V10, P1131
  • [9] Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
    Chen, Tingkai
    Li, Qi
    Liu, Zongliang
    Chen, Yao
    Feng, Feng
    Sun, Haopeng
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 161 : 378 - 398
  • [10] Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer
    Cui, Yong
    Li, Guanlong
    Zhang, Xin
    Dai, Fangfang
    Zhang, Rongxiang
    [J]. ONCOLOGY LETTERS, 2018, 16 (04) : 4821 - 4828